secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medtronic plc (MDT)
CIK:        0001613103
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001628280-26-008300
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medtronic Q3 FY2026: Revenue $9.02B (+6% organic), non-GAAP EPS $1.36 beats guidance; reiterates FY outlook
--------------------------------------------------------------------------------

- GAAP diluted EPS $0.89; non-GAAP diluted EPS $1.36, three cents above Q3 guidance mid-point.
- Cardiovascular portfolio revenue $3.46B (+10.6% organic); Cardiac Ablation Solutions up 80% on pulsed field ablation.
- Diabetes revenue $796M (+8.3% organic); Neuroscience $2.56B (+2.5% organic); Medical Surgical $2.17B (+2.7% organic).
- Reiterates FY26 organic revenue growth ~5.5% and non-GAAP EPS guidance $5.62-$5.66, including ~$185M tariff impact.
- Secured FDA clearances for Hugo robotic-assisted surgery and Stealth AXiS; CE Mark for Sphere-360; completed CathWorks and Anteris acquisitions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613103/000162828026008300/0001628280-26-008300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613103/000162828026008300/mdt-20260217.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-008300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer